1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Physician Views: How will neurologists embrace Teva’s new version of Copaxone? What about potential generic versions later this year?

Scope

The US multiple sclerosis market is expected to evolve notably in 2014, with analysts now confident that the FDA will approve at least one generic version of Teva's Copaxone when exclusivity expiries in May.

From a commercial perspective, Teva will seek to defend loss of share to generic competition via the launch of a more convenient version of Copaxone, which is dosed three times a week rather than once-daily.

FDA approval for this formulation was secured last week and Teva plans an immediate launch which will be supported by modest list price discounting versus the existing Copaxone brand (reported to be between 2 percent and 8 percent by various sources) - ViewPoints: Do Teva's Copaxone sums add up?

Last month, Teva's chief science officer Michael Hayden said that the company expects to switch around 45 percent of existing Copaxone patients onto the longer-acting formulation (including an aggressive 35 percent switch by June), in order to preserve some patient base prior to the potential launch of generic competition.

The company has become increasingly confident in its ability to convert patients, noted analysts at Bloomberg Industries last week; in late 2012, for example, Teva was suggesting that it could switch around a third of patients to the newer formulation.

Despite newer oral therapies – spearheaded by the launch of Biogen Idec's Tecfidera last year – having made in-roads into the MS market, prescription data illustrates that Copaxone continues to perform robustly. As one US-based key opinion leader told FirstWord's Therapy Trends team last year, "Copaxone still has a role to play in disease management, particularly when we have been using it for a long time with no real safety issues."

How neurologists utilise any generic version of Copaxone, should one or multiple products gain FDA approval later this year, could emerge as one of the most interesting dynamics in the MS market for some time. Teva continues to argue that the complexity of Copaxone should preclude FDA approval of generic versions not supported by full pivotal-stage clinical data, while KOLs have expressed their own concerns to FirstWord about potential usage of such a product.


Reasons to Buy this Report

This week's Physician Views poll will ask US-based neurologists:

• Approximately what percentage of existing Copaxone patients do you expect to switch to the new three-times weekly formulation (approved by the FDA last week) by mid-2014?
• Moving away from a once-daily dosing profile, are you concerned about non-compliance issues with the three-times weekly versions?
• Assuming the FDA approves a generic version of Copaxone later this year (patent exclusivity expires in May), and based on your knowledge of the product, how comfortable would you be switching an existing Copaxone patient to a generic version?
• How comfortable would you be prescribing generic Copaxone as a first-line injectable therapy (i.e. instead of branded Copaxone or the interferon agents)?
• Approximately what percentage of newly diagnosed MS patients are you currently treating with Copaxone in a first-line setting?



Table Of Contents

Physician Views: How will neurologists embrace Teva’s new version of Copaxone? What about potential generic versions later this year?

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
2016 Immunodiagnostic Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Special Chemistry, Drug of Abuse, Endocrine Function, Immunoprotein, Therapeutic Drug Monitoring, and Tumor Marker Tests,  Opport

2016 Immunodiagnostic Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Special Chemistry, Drug of Abuse, Endocrine Function, Immunoprotein, Therapeutic Drug Monitoring, and Tumor Marker Tests, Opport

  • $ 47500
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-company survey from VPGMarketResearch.com contains 1,650 pages and 890 tables. The report provides a granular strategic analysis of over 100 clinical chemistry, TDM, endocrine, cancer, immunoprotein ...

2016 Tumor Markers in 32 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppliers

2016 Tumor Markers in 32 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppliers

  • $ 47400
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,300 pages and 500 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...

2016 Cancer Diagnostic Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Tumor Marker--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Technology Trends

2016 Cancer Diagnostic Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Tumor Marker--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Technology Trends

  • $ 47400
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,300 pages and 500 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...


ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.